SARS-CoV-2-Triggered Hemophagocytic Lymphohistiocytosis with Complications of Posterior Reversible Encephalopathy Syndrome.
Ross M PerryScott D CaseyAlex Q LeeSylvia P BowditchMary A RasmussenViyeka SethiArun R PanigrahiPublished in: Case reports in pediatrics (2024)
In this article, we describe a novel case of SARS-CoV-2-associated-hemophagocytic lymphohistiocytosis (HLH) complicated by posterior reversible encephalopathy syndrome (PRES). Initially diagnosed with multisystem inflammatory response in children (MIS-C), the patient received a large corticosteroid dose days before the onset of neurological symptoms. After developing PRES, the patient was treated with antihypertensives, antiepileptics, dexamethasone, and anakinra, leading to neurologic normalization. We propose that given the challenging diagnostic picture of PRES developing in patients with HLH or MIS-C, institutionalized standards for blood pressure management during corticosteroid induction may significantly improve outcomes in patients being treated for hyperinflammatory syndromes who develop neurological symptoms.
Keyphrases
- sars cov
- case report
- inflammatory response
- blood pressure
- newly diagnosed
- end stage renal disease
- respiratory syndrome coronavirus
- ejection fraction
- chronic kidney disease
- early onset
- peritoneal dialysis
- prognostic factors
- sleep quality
- low dose
- immune response
- toll like receptor
- type diabetes
- hypertensive patients
- brain injury
- physical activity
- blood glucose
- weight loss
- adipose tissue
- cerebral ischemia
- insulin resistance